Caribou Biosciences

Caribou Biosciences

生物技术研究

Berkeley,CA 34,481 位关注者

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases

关于我们

Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases.

网站
https://cariboubio.com
所属行业
生物技术研究
规模
51-200 人
总部
Berkeley,CA
类型
上市公司
创立
2012
领域
Next-generation CRISPR genome editing、allogeneic CAR-T cell therapies、oncology和autoimmune

地点

  • 主要

    2929 7th St, Suite 105

    US,CA,Berkeley,94710

    获取路线

Caribou Biosciences员工

动态

相似主页

查看职位

融资

Caribou Biosciences 共 9 轮

上一轮

上市后股权

US$125,000,000.00

Crunchbase 上查看更多信息